Atlas Trials

Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis

Clinical trial NCT02565576 · COMPLETED

Trial details

NCT number
NCT02565576
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Myasthenia Gravis, Generalized
Start date
2015-09-29
Primary completion
2017-07-31
Enrollment
44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.